Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Brain Neoplasms 25Breast Neoplasms 20Meningeal Carcinomatosis 4Neoplasms 3Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Meningeal Neoplasms 2Melanoma 2Lung Neoplasms 2Glioma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Neoplasms 1Urethral Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × Trastuzumab × CNS × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡